LPCN
Lipocine Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.52
+0.66%Year over year
Reported trailing growth
- Revenue
- -62.7%
- EBITDA
- —
- EBIT
- —
- EPS
- —
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -70.5%
- EBITDA
- +18.6%
- EPS
- +37.2%
Three-year CAGR
- Revenue
- +58.1%
- EBITDA
- —
- EBIT
- —
- Net income
- —
- EPS
- —
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026